News ArticleVA Tech Wabag to Host Conference Call on November 6 for Q2 and H1 FY27 Financial Results
Call will feature Chairman Rajiv Mittal and CFO Skandaprasad Seetharaman discussing unaudited standalone and consolidated results
VA Tech Wabag Limited announced its schedule for the investor conference call to discuss unaudited financial results for Q2 and H1 FY27, to be held on November 6, 2026. The company will host a conference call with investors, analysts and stakeholders with key management participation, presenting both standalone and consolidated results.
VA Tech Wabag Limited
Investor Presentation
VA Tech Wabag Limited announced it will conduct an investor conference call on November 6, 2026, at 4:00 PM IST to discuss its unaudited financial results for the second quarter and first half of fiscal year 2027, covering both standalone and consolidated financials.
The conference call will enable investors, analysts, and other stakeholders to engage directly with the company's top management, including Chairman and Managing Director Rajiv Mittal and Chief Financial Officer Skandaprasad Seetharaman.
The company stated that the results presentation will be made available on its website and stock exchange portals prior to the call. The meeting will not include any unpublished price sensitive information.
Participants can join the call via the given toll-free numbers in India, USA, UK, Singapore, and Hong Kong. The event is hosted by VA Tech Wabag’s investor relations with RSVP contact details provided.
Highlights
- Conference call scheduled for November 6, 2026, at 4:00 PM IST
- Discussion of unaudited Q2 and H1 FY27 standalone and consolidated financial results
- Key management participants: Chairman Rajiv Mittal and CFO Skandaprasad Seetharaman
- Presentation to be uploaded on company and stock exchange websites before the call
- Multiple international toll-free dial-in numbers provided for participation
Key Data Snapshot
What happened
- VA Tech Wabag announced a scheduled investor conference call to discuss its unaudited financial results for Q2 and H1 FY27, both standalone and consolidated.
- The call is organized for November 6, 2026 at 4:00 PM IST.
- The event will not disclose any unpublished price sensitive information.
Key details
- The financial results presentation will be uploaded on the company and stock exchange websites before the call.
- Investors and analysts can join the call via multiple toll-free numbers in India, USA, UK, Singapore and Hong Kong.
- Participants include Chairman and Managing Director Rajiv Mittal and CFO Skandaprasad Seetharaman.
Regulatory and governance context
- Announcement made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30.
- The company secretary and compliance officer Anup Kumar Samal signed the intimation letter.
Highlights
- Conference call scheduled for November 6, 2026, at 4:00 PM IST
- Discussion of unaudited Q2 and H1 FY27 standalone and consolidated financial results
- Key management participants: Chairman Rajiv Mittal and CFO Skandaprasad Seetharaman
- Presentation to be uploaded on company and stock exchange websites before the call
- Multiple international toll-free dial-in numbers provided for participation
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
GlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
